Intravitreal Steroids for the Treatment of Macular Edema in Retinal Vein Occlusions

2015 ◽  
pp. 69-79
Author(s):  
Eran Zunz ◽  
Anat Loewenstein

Macular edema secondary to retinal vein occlusions is a significant complication affecting the vision. Medical treatment of retinal vein occlusions first started with intraocular steroid injections and then enriched with intraocular Anti-VEGF (Vascular Endothelial Growth Factor) injections. But till now the length and frequency of therapy have not been defined clearly. In this review, the use of bevacizumab in the treatment of branch retinal vein occlusion and macular edema will be summarized in light of the current literature.


Ophthalmology ◽  
2008 ◽  
Vol 115 (10) ◽  
pp. e47-e54 ◽  
Author(s):  
Dante J. Pieramici ◽  
Melvin Rabena ◽  
Alessandro A. Castellarin ◽  
Ma'an Nasir ◽  
Robert See ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Nicolas Arej ◽  
Vivien Vasseur ◽  
Elyse Jabbour ◽  
Anthony Manassero ◽  
Céline Giraud ◽  
...  

Central retinal vein occlusion (CRVO) is a common retinal disease. Recent works mentioned spontaneous retinal arterial pulsations (SRAPs) as a feature of some CRVOs. This is a retrospective study on patients presenting with CRVO who were followed up for at least 6 months. The objective was to identify SRAP in the acute phase of the disease and determine their relationship with patients’ characteristics and visual prognosis. A 10-second infrared film centered on the optic disc was recorded within a month of the onset of symptoms, and SRAPs were detected in two-thirds of the cases. Patients with SRAP were significantly younger than those without SRAP. Mean central macular thickness was significantly higher in the absence of SRAP, which was translated into a more severe macular edema; however, this difference faded with time. BCVA tended to be higher in the presence of SRAP at the 6-month follow-up when adjusted to baseline. This study demonstrates that SRAPs are a frequent finding, easily detected by infrared fundus video recording, and associated with a younger age and lesser macular edema.


2011 ◽  
Vol 6 (5) ◽  
pp. 557-564 ◽  
Author(s):  
Antonio P Ciardella ◽  
Mariachiara Morara ◽  
Francesco Pichi ◽  
Micol Alkabes ◽  
Simona Romano ◽  
...  

2015 ◽  
Vol 8 (1) ◽  
pp. 79-88
Author(s):  
Anastasiya Viktorovna Kulagina ◽  
Evgeniy Gennad'evich Badazhkov ◽  
Olga Gennad’evna Gusarevich

A clinical efficacy analysis of combined post-thrombotic retinopathy treatment using dexamethason intravitreal implant “Ozurdex” and retinal photocoagulation is presented. The medication promotes macular edema resorption and allows increasing visual acuity for a long period of time. Photocoagulation prevents complications, promotes edema and hemorrhage resorption. Visual acuity dynamics may be influenced by such factors as disease duration, lesion area, occlusion localization. The use of dexamethason intravitreal implant in combination with photocoagulation gives new options in treatment of patients with retinal vein occlusions


2012 ◽  
Vol 4 ◽  
pp. OED.S7264
Author(s):  
Roberto Gallego-Pinazo ◽  
Rosa Dolz-Marco ◽  
Cristina Marín-Lambíes ◽  
Manuel Díaz-Llopis

Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.


Sign in / Sign up

Export Citation Format

Share Document